Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Fosun Pharma’s Hong Kong IPO Set to Raise $600 Million

publication date: Oct 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Fosun Pharma’s long-in-the-works IPO on the Hong Kong exchange is scheduled to take place this month, raising a diminished $600 million. The company received regulatory approval for the offering five months ago, but market conditions have held the transaction back until now – and caused the company to drop the projected take from $800 million. There have been no IPOs in Hong Kong for the last three months. More details....

Stock Symbol: (SHA: 600196)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors